Neurogastrx grabbed $45 million to bring its gastroparesis drug through proof of concept.

Next year will be a busy time for the European Medicines Agency as it looks to complete its move to Amsterdam.

While 2016 was a year of cancelled and low-end IPOs, 2017 was a year marked by IPO momentum.

If you took charge of a sizable biopharma company in 2017, there was one thing you had to do.

The former CEO of Tennessee biotech Provectus treated the company as his “personal piggy bank,” taking millions from the business, says the SEC.

PsiOxus Therapeutics has a green light for trials of its cancer-killing virus therapy for solid tumors, sparking a $15 million milestone payment.

The lure of a razor-sharp therapeutic focus has enticed AstraZeneca’s head of early clinical development, Tony Johnson, to take the top job at kidney disease…

ValiRx is approaching a pivotal point in its development as it waits for clinical results from two lead programs.